Souhaitez-vous accéder aux communiqués récents ?

CME Outfitters and Zealic Health announce a collaboration focused on preparing health care practitioners for the realities of psychedelic therapy delivery.

The FDA's Sept. 14 public hearing on the potential future therapeutic use of psychedelic drugs marks one of the most significant regulatory moments for the field.The FDA is accepting written testimony...

The reported resubmission of the New Drug Application will initiate a new evaluation of the treatment’s safety and efficacy for potential FDA approvalRecently updated FDA guidance, Psychedelic Drugs:...

America is cleaning out the wounds, getting rid of the infections, stopping the bleeding, applying medicines, administering therapies and strongly healing.

Founded in April 1986 to advance psychedelic research and knowledge, MAPS has raised more than $150 million, supported 45 studies, and shaped the global policy and cultural landscape of...

Anonymous survey with optional confidential interviews will document how practitioners facilitate MDMA-assisted couples therapyFindings to inform ethical guidelines, future clinical trial protocols,...

Training supports multi-site clinical trial of MDMA-assisted Massed Prolonged Exposure Therapy for PTSD in active-duty service members.First-of-its-kind therapist preparation supports the Department...

MAPS brings MDMA-assisted therapy training to Poland for the first time, awarding scholarships to 20 practitioners from war-affected Ukraine and Palestine.

MAPS names Betty Aldworth and Ismail Lourido Ali as Co-Executive Directors, bringing decades of drug policy expertise.

Enhanced Virtual Trip platform goes live with improved user experience and first selection of PS2025 session videosConference drew 8,000+ attendees, more than $1 million donated, and 1,100+ recurring...